TICAROS Co., Ltd.
TiCARos is a biotech company developing next-generation immune anticancer drugs. They focus on advanced immunotherapy and antibody technology, aiming to create innovative treatments for intractable cancers. Their platforms include Converter CAR, CLIP CAR, and CAR-T therapies, which enhance T cell activation and stabilize immune synapses to improve cancer treatment efficacy.
Industries
Nr. of Employees
small (1-50)
TICAROS Co., Ltd.
Patents
Products
Immuno-oncology CAR-based therapeutic candidates
Pipeline of engineered CAR-based cell therapy candidates designed to enhance tumor-specific effector activity and reduce systemic autoimmune effects for treatment of refractory/advanced cancers.
Immuno-oncology CAR-based therapeutic candidates
Pipeline of engineered CAR-based cell therapy candidates designed to enhance tumor-specific effector activity and reduce systemic autoimmune effects for treatment of refractory/advanced cancers.
Services
Co-development agreements and licensing arrangements to advance CAR-based cell therapy technologies with external partners.
Co-development agreements and licensing arrangements to advance CAR-based cell therapy technologies with external partners.
Expertise Areas
- Immuno-oncology therapeutic development
- CAR construct engineering
- Cell therapy platform development
- Selective immune checkpoint modulation
Key Technologies
- CAR-T therapy
- CAR backbone engineering
- Immunological synapse stabilization
- Immune checkpoint modulation
News & Updates
TiCARos published a paper on 'Switchable CAR-T' technology in Nature Communications.
TiCARos was selected by J-Labs Korea and received support from Johnson & Johnson.
TiCARos and Cellectis filed a joint patent application for 'CLIP-CAR-NK' in Australia.
TiCARos published a paper on 'Switchable CAR-T' technology in Nature Communications.
TiCARos was selected by J-Labs Korea and received support from Johnson & Johnson.
TiCARos and Cellectis filed a joint patent application for 'CLIP-CAR-NK' in Australia.